Table 2.
Prospective studies involving the use of single-fraction SBRT in the treatment of extracranial/extraspinal oligometastatic disease
| Authors (year) | Study type | Primary diagnosis | No. patients | No. metastases | Treated site(s) | Dose (Gy) | Median follow-up (months) | Local control | Acute/late grade ≥3 toxicity |
|---|---|---|---|---|---|---|---|---|---|
| Siva et al (2018)72 | Phase I/II | Prostate | 33 | 50 | Bone, lymph node, or both | 20 | NR | 1 y 97% 2 y 93% |
3% |
| David et al (2020)71 | Phase I/II | Breast | 15 | 19 | Bone | 20 | 24 | 2 y 100% | 0% acute |
| Nuyttens et al (2015)77 | Phase II | Multiple | 30 | 57 | Lung | 30 | 36 | 2 y 74% | 17% acute 10% late |
| Goodman et al (2010)85 | Phase I | Multiple | 26 | 40 | Liver | 18-30 | 17.3 | 1 y 77% | 0% |
| Meyer et al (2016)86 | Phase I | Multiple | 14 | 17 | Liver | 35-40 | 30 | 2 y 100% | 0% |
Abbreviations: NR = not reported; SBRT = stereotactic body radiation therapy.